KB-3061 Earns Rare Pediatric Disease Designation for Treatment of KCNQ2-EE

  In a recent press release, Knopp Biosciences announced that their drug therapy KB-3061 was granted Rare Pediatric Disease Designation to treat patients with KCNQ2 epileptic encephalopathy (KCNQ2-EE), a rare…

Continue Reading KB-3061 Earns Rare Pediatric Disease Designation for Treatment of KCNQ2-EE
Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
source: pixabay.com

Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease

  According to a recent article in BioSpace, Biogen and Eisai have launched a new preclinical Phase III trial of BAN2401 to treat pre-clinical Alzheimer's disease. The new study follows…

Continue Reading Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
An Interview With the Founder of AccessNow: COVID-19 and the Disabled Community
source: pixabay.com

An Interview With the Founder of AccessNow: COVID-19 and the Disabled Community

  For twenty-five years Women of Influence has focused on empowering and helping to advance women in the workforce. Maayan Ziv, a Canadian tech entrepreneur, disability advocate, and voted one…

Continue Reading An Interview With the Founder of AccessNow: COVID-19 and the Disabled Community
Ibrutinib-Ublituximab Combo Leads to Better Outcomes for Patients with CLL
source: pixabay.com

Ibrutinib-Ublituximab Combo Leads to Better Outcomes for Patients with CLL

  According to CLL Pharmacist, results from the Phase 3 GENUINE trial show that, when taken in conjunction, ibrutinib and ublituximab lead to better patient outcomes than either drug alone.…

Continue Reading Ibrutinib-Ublituximab Combo Leads to Better Outcomes for Patients with CLL
CC-486 Improves Myelodysplastic Syndromes Patient’s Transfusion Independence But With Significant Adverse Reactions
source: pixabay.com

CC-486 Improves Myelodysplastic Syndromes Patient’s Transfusion Independence But With Significant Adverse Reactions

  Results of a Phase III study of CC-486 (oral form of azacitidine) showed a significant improvement for older patients who had been transfusion dependent. The results were favorable when…

Continue Reading CC-486 Improves Myelodysplastic Syndromes Patient’s Transfusion Independence But With Significant Adverse Reactions
Close Menu